Resistance in Hematologic Malignancies and Cancer

Herausgeber: Messingerova, Lucia; Breier, Albert

• Gebundenes Buch

Produktbeschreibung

Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science
• Seitenzahl: 326
• Erscheinungstermin: 5. November 2024
• Englisch
• Gewicht: 450g
• ISBN-13: 9780443217906
• ISBN-10: 0443217904
• Artikelnr.: 70675839

Inhaltsangabe

1. Drug classification for treatment Hematological Malignancies
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics
and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death
balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to
chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via
the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to
overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)